Search Results for: Samsung
Trials & Approvals Lung Cancer
Novartis’s Lung Cancer Drug Approved for Marketing in Europe
2022-06-23
Licensing China
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Licensing CDMO
Novartis and Samsung Biologics Sign Low-Profile $81 Million Deal
2022-06-10
Deals Eye Development
Bio-Europe Spring: 2022 Europe Ophthalmic Medication Market Skyrockets
2022-04-20
M&A Biosimilar
BBL to Take Over Biosimilars Business from Viatris 
2022-03-02
Technology HUMIRA
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
2022-02-16
Asia-Pacific Cell Therapy
AbClon, HK inno.N Collaborates to Take On Novartis’ CAR T-Cell Therapy
2022-02-15
Trials & Approvals COVID-19 Vaccine
It’s Official! Moderna’s COVID Vaccine Receives FDA Approval
2022-02-02
Asia-Pacific Biosimilar
Samsung Biologics Snaps Up Biogen’s Stake in Samsung Bioepis for $2.3 Billion, Assuming Full Control of Biosimilar Venture
2022-01-28
Interviews CDMO
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
Asia-Pacific CDMO
Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics
2021-11-30
Asia-Pacific Samsung Biologics
Samsung Biologics Strikes Deal with GreenLight Bio to Manufacture mRNA Vaccines
2021-11-29
Asia-Pacific COVID-19
South Korea Approves EUA for Moderna’s COVID-19 Vaccine Produced by Samsung Biologics
2021-10-28
Interviews Taiwan
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Asia-Pacific COVID-19 Vaccine
Samsung Biologics Initiates Production of Moderna’s COVID-19 Vaccine
2021-10-15
1 2 3 4 5
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top